Polysaccharide specific monoclonal antibodies provide passive protection against intranasal challenge with burkholderia pseudomallei

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  AuCoin, David P ^a   Reed, Dana E ^a   Marlenee, Nicole L ^b   Bowen, Richard A ^b   Thorkildson, Peter ^a   Judy, Barbara M ^c   Torres, Alfredo G ^c   Kozel, Thomas R ^a  

^a UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

^b Department of Environmental and Radiological Health Sciences   (United States)

^c University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL POLYSACCHARIDE; BACTERIUM LIPOPOLYSACCHARIDE; CAPSULAR POLYSACCHARIDE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 3C5; MONOCLONAL ANTIBODY 4C7; UNCLASSIFIED DRUG;

ABSCESS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL STRAIN; BURKHOLDERIA PSEUDOMALLEI; COLONY FORMING UNIT; CONTROLLED STUDY; MELIOIDOSIS; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; SPLEEN; SURVIVAL RATE;

ABSCESS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, BACTERIAL; BURKHOLDERIA PSEUDOMALLEI; EPITOPES; FEMALE; IMMUNIZATION, PASSIVE; MELIOIDOSIS; MICE; MICE, INBRED BALB C; POLYSACCHARIDES; SPLEEN;

BACILLUS (BACTERIUM); BACTERIA (MICROORGANISMS); BURKHOLDERIA PSEUDOMALLEI; MUS; NEGIBACTERIA;

EID: 84859820563     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0035386     Document Type: Article

References (43)

1. Dance DA, Wuthiekanun V, Chaowagul W, White NJ, (1989) The antimicrobial susceptibility of Pseudomonas pseudomallei. Emergence of resistance in vitro and during treatment. J Antimicrob Chemother 24: 295-309.
2. White NJ, (2003) Melioidosis. Lancet 361: 1715-1722.
3. Jenney AW, Lum G, Fisher DA, Currie BJ, (2001) Antibiotic susceptibility of Burkholderia pseudomallei from tropical northern Australia and implications for therapy of melioidosis. Int J Antimicrob Agents 17: 109-113.
4. Estes DM, Dow SW, Schweizer HP, Torres AG, (2010) Present and future therapeutic strategies for melioidosis and glanders. Expert Rev Anti Infect Ther 8: 325-338.
5. Chaowagul W, Suputtamongkol Y, Dance DA, Rajchanuvong A, Pattara-arechachai J, et al. (1993) Relapse in melioidosis: incidence and risk factors. J Infect Dis 168: 1181-1185.
6. Limmathurotsakul D, Wongratanacheewin S, Teerawattanasook N, Wongsuvan G, Chaisuksant S, et al. (2010) Increasing incidence of human melioidosis in Northeast Thailand. Am J Trop Med Hyg 82: 1113-1117.
7. Cheng AC, Hanna JN, Norton R, Hills SL, Davis J, et al. (2003) Melioidosis in northern Australia, 2001-02. Commun Dis Intell 27: 272-277.
8. Reckseidler SL, DeShazer D, Sokol PA, Woods DE, (2001) Detection of bacterial virulence genes by subtractive hybridization: identification of capsular polysaccharide of Burkholderia pseudomallei as a major virulence determinant. Infect Immun 69: 34-44.
9. Reckseidler-Zenteno SL, DeVinney R, Woods DE, (2005) The capsular polysaccharide of Burkholderia pseudomallei contributes to survival in serum by reducing complement factor C3b deposition. Infect Immun 73: 1106-1115.
10. Charuchaimontri C, Suputtamongkol Y, Nilakul C, Chaowagul W, Chetchotisakd P, et al. (1999) Antilipopolysaccharide II: an antibody protective against fatal melioidosis. Clin Infect Dis 29: 813-818.
11. Arjcharoen S, Wikraiphat C, Pudla M, Limposuwan K, Woods DE, et al. (2007) Fate of a Burkholderia pseudomallei lipopolysaccharide mutant in the mouse macrophage cell line RAW 264.7: possible role for the O-antigenic polysaccharide moiety of lipopolysaccharide in internalization and intracellular survival. Infect Immun 75: 4298-4304.
12. DeShazer D, Brett PJ, Woods DE, (1998) The type II O-antigenic polysaccharide moiety of Burkholderia pseudomallei lipopolysaccharide is required for serum resistance and virulence. Mol Microbiol 30: 1081-1100.
13. Woods DE, DeShazer D, Moore RA, Brett PJ, Burtnick MN, et al. (1999) Current studies on the pathogenesis of melioidosis. Microbes Infect 1: 157-162.
14. Ho M, Schollaardt T, Smith MD, Perry MB, Brett PJ, et al. (1997) Specificity and functional activity of anti-Burkholderia pseudomallei polysaccharide antibodies. Infect Immun 65: 3648-3653.
15. Perry MB, MacLean LL, Schollaardt T, Bryan LE, Ho M, (1995) Structural characterization of the lipopolysaccharide O antigens of Burkholderia pseudomallei. Infect Immun 63: 3348-3352.
16. Knirel YA, Paramonov NA, Shashkov AS, Kochetkov NK, Yarullin RG, et al. (1992) Structure of the polysaccharide chains of Pseudomonas pseudomallei lipopolysaccharides. Carbohydr Res 233: 185-193.
17. Nuti DE, Crump RB, Dwi Handayani F, Chantratita N, Peacock SJ, et al. (2011) Identification of circulating bacterial antigens by in vivo microbial antigen discovery. mBio 2.
18. Jones SM, Ellis JF, Russell P, Griffin KF, Oyston PC, (2002) Passive protection against Burkholderia pseudomallei infection in mice by monoclonal antibodies against capsular polysaccharide, lipopolysaccharide or proteins. J Med Microbiol 51: 1055-1062.
19. Kozel TR, Murphy WJ, Brandt S, Blazar BR, Lovchik JA, et al. (2004) mAbs to Bacillus anthracis capsular antigen for immunoprotection in anthrax and detection of antigenemia. Proc Natl Acad Sci U S A 101: 5042-5047.
20. Whitlock GC, Valbuena GA, Popov VL, Judy BM, Estes DM, et al. (2009) Burkholderia mallei cellular interactions in a respiratory cell model. J Med Microbiol 58: 554-562.
21. Kozel TR, Thorkildson P, Brandt S, Welch WH, Lovchik JA, et al. (2007) Protective and immunochemical activities of monoclonal antibodies reactive with the Bacillus anthracis polypeptide capsule. Infect Immun 75: 152-163.
22. Anuntagool N, Aramsri P, Panichakul T, Wuthiekanun VR, Kinoshita R, et al. (2000) Antigenic heterogeneity of lipopolysaccharide among Burkholderia pseudomallei clinical isolates. Southeast Asian J Trop Med Public Health 31 (Suppl 1): 146-152.
23. Anuntagool N, Intachote P, Wuthiekanun V, White NJ, Sirisinha S, (1998) Lipopolysaccharide from nonvirulent Ara+ Burkholderia pseudomallei isolates is immunologically indistinguishable from lipopolysaccharide from virulent Ara- clinical isolates. Clin Diagn Lab Immunol 5: 225-229.
24. Anuntagool N, Sirisinha S, (2002) Antigenic relatedness between Burkholderia pseudomallei and Burkholderia mallei. Microbiol Immunol 46: 143-150.
25. Zou N, Tsai S, Feng SH, Newsome T, Kim HY, et al. (2008) Relationship between antigenicity and pathogenicity for Burkholderia pseudomallei and Burkholderia mallei revealed by a large panel of mouse MAbs. Hybridoma (Larchmt) 27: 231-240.
26. Chou TC, Motzer RJ, Tong Y, Bosl GJ, (1994) Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 86: 1517-1524.
27. Chou TC, Talalay P, (1983) Analysis of combined drug effects: A new look at a very old problem. Trends Pharmacol 4: 450-454.
28. Bryan LE, Wong S, Woods DE, Dance D, Chaowagul W, (1995) Passive protection of diabetic rats with antisera specific for the polysaccharide portion of the lipopolysaccharide isolated from Pseudomonas pseudomallei. Can J Infect Dis 5: 170-178.
29. Nelson M, Prior JL, Lever MS, Jones HE, Atkins TP, et al. (2004) Evaluation of lipopolysaccharide and capsular polysaccharide as subunit vaccines against experimental melioidosis. J Med Microbiol 53: 1177-1182.
30. Brett PJ, Woods DE, (1996) Structural and immunological characterization of Burkholderia pseudomallei O-polysaccharide-flagellin protein conjugates. Infect Immun 64: 2824-2828.
31. Zhang S, Feng SH, Li B, Kim HY, Rodriguez J, et al. (2011) In Vitro and In Vivo Studies of Monoclonal Antibodies with Prominent Bactericidal Activity against Burkholderia pseudomallei and Burkholderia mallei. Clin Vaccine Immunol 18: 825-834.
32. Bottex C, Gauthier YP, Hagen RM, Finke EJ, Splettstosser WD, et al. (2005) Attempted passive prophylaxis with a monoclonal anti-Burkholderia pseudomallei exopolysaccharide antibody in a murine model of melioidosis. Immunopharmacol Immunotoxicol 27: 565-583.
33. Reckseidler-Zenteno SL, Moore R, Woods DE, (2009) Genetics and function of the capsules of Burkholderia pseudomallei and their potential as therapeutic targets. Mini Rev Med Chem 9: 265-271.
34. Taborda CP, Casadevall A, (2001) Immunoglobulin M efficacy against Cryptococcus neoformans: mechanism, dose dependence, and prozone-like effects in passive protection experiments. Journal of immunology 166: 2100-2107.
35. Taborda CP, Rivera J, Zaragoza O, Casadevall A, (2003) More is not necessarily better: prozone-like effects in passive immunization with IgG. Journal of immunology 170: 3621-3630.
36. Zaragoza O, Alvarez M, Telzak A, Rivera J, Casadevall A, (2007) The relative susceptibility of mouse strains to pulmonary Cryptococcus neoformans infection is associated with pleiotropic differences in the immune response. Infection and immunity 75: 2729-2739.
37. Sarkar-Tyson M, Titball RW, (2010) Progress toward development of vaccines against melioidosis: A review. Clin Ther 32: 1437-1445.
38. Currie BJ, Fisher DA, Anstey NM, Jacups SP, (2000) Melioidosis: acute and chronic disease, relapse and re-activation. Trans R Soc Trop Med Hyg 94: 301-304.
39. Panomket P, Chetchotisakd P, Sermswan RW, Pannengpetch P, Wongratanacheewin S, (2009) Use of a low-dose steroid as an adjunct in the treatment, in mice, of severe sepsis caused by Burkholderia pseudomallei. Annals of tropical medicine and parasitology 103: 635-646.
40. Cheng AC, Stephens DP, Anstey NM, Currie BJ, (2004) Adjunctive granulocyte colony-stimulating factor for treatment of septic shock due to melioidosis. Clin Infect Dis 38: 32-37.
41. Cheng AC, Dasari P, Currie BJ, (2004) Granulocyte colony-stimulating factor and an in vitro whole blood model of melioidosis. Eur J Clin Microbiol Infect Dis 23: 205-207.
42. Powell K, Ulett G, Hirst R, Norton R, (2003) G-CSF immunotherapy for treatment of acute disseminated murine melioidosis. FEMS Microbiol Lett 224: 315-318.
43. Propst KL, Troyer RM, Kellihan LM, Schweizer HP, Dow SW, (2010) Immunotherapy markedly increases the effectiveness of antimicrobial therapy for treatment of Burkholderia pseudomallei infection. Antimicrobial agents and chemotherapy 54: 1785-1792.